Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

EPICOS (Polo) RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
231/223 inconclusive
    HERO-HCQ (Naggie)
     
    NCT04334148
    RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
    683/676 inconclusive
      Rojas-Serrano
       
      NCT04318015
      RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
      65/65 inconclusive
      • inconclusive 84 % decrease in symptomatic Covid-19,infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
      Seet (HCQ) RCThydroxychloroquinevitamin CCOVID-19 prophylaxis (excluding children)some concern
      432/619 suggested
        Barnabas RV
         
        NCT04328961
        RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
        407/422 safety concern
        • inconclusive 10 % increase in infection (PCR positive symptomatic or not) (PE) with a high degree of certainty due to low risk of bias
        • statistically significant 58 % increase in adverse events with a high degree of certainty due to low risk of bias
        BCN PEP-CoV-2-Study 1 (Mitja NEJM)
         
        NCT04304053
        RCThydroxychloroquinestandard of careCOVID-19 prophylaxis (excluding children)some concern
        1116/1198 safety concern
        • inconclusive 14 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • statistically significant 19.3-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        COVID PREP HCQ (2x week, Rajasingham)
         
        NCT04328467
        RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
        495/494 safety concern
        • inconclusive 26 % decrease in infection (PCR positive symptomatic or not) (PE) with a high degree of certainty due to low risk of bias
        • statistically significant 1.0-fold increase in adverse events with a high degree of certainty due to low risk of bias
        COVID-PEP-Post exposure (Boulware)
         
        NCT04308668
        RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
        414/407 safety concern
        • statistically significant 2.3-fold increase in adverse events with a high degree of certainty due to low risk of bias
        PATCH-cohort 3 PreP (Abella)
         
        NCT04329923
        RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
        66/66 inconclusive
        • inconclusive 5 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
        6 studies excluded by filtering options (3 RCT / 3 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).